Current approach to the acute management of cryptococcal infections.
Powderly
W G
WG
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D003455:Cryptococcus neoformans / Q000187:drug effects*; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D016919:Meningitis, Cryptococcal / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine